Box heads into the week with an unusual tension: short interest has climbed sharply over the past month while options traders remain among the most call-heavy in the past year.
Short positioning has become the defining story. Short interest is now 12.6% of the free float — a genuinely elevated level for an application software name — and has risen nearly 20% over the past 30 days, with another 2.8% added in the past week alone. That 30-day build, from roughly 15.2 million shares to 18.2 million, is the most sustained one-direction move in the history window here. The lending market, however, offers no amplification: availability is abundant at 565% of short interest, cost to borrow is just 0.44% and has been drifting lower, and borrow conditions have loosened further compared to a month ago. Short sellers are building positions, but they are doing so cheaply and without any squeeze pressure.
Options positioning tells a strikingly different story. The put/call ratio has dropped to 0.22, about one standard deviation below its 20-day average — making this one of the most call-skewed readings of the past year, against a 52-week range of 0.09 to 0.72. Options traders are not hedging; they are leaning into upside. That disconnect — shorts rebuilding while call buyers dominate options flow — is the clearest signal that the market has not yet reached consensus on where Box goes next.
The Street is similarly divided. Most analyst moves following the late-August earnings print were constructive: Citigroup raised its target to $40 (Buy), DA Davidson lifted to $50 (also Buy), and Morgan Stanley pushed its target up to $36 even while holding at Equal-Weight. UBS made the sharpest revision, raising from $29 to $37 while staying Neutral. The outlier is RBC Capital, which kept its Underperform rating and $26 target unchanged — the only name on the register actively calling for downside from current levels. The consensus rating is technically "sell," but that single Underperform appears to be dragging the blended score; the majority of named coverage is neutral to bullish. Mean target of $38.71 implies modest upside from the $32.87 close. On valuation, the PE ratio is running near 19.5x and EV/EBITDA at 11.6x, both drifting slightly lower over the past 30 days.
The factor picture adds another layer of caution. The short score of 60.6 has crept higher across September, and the short score rank sits in the 13th percentile — meaning Box is more shorted than roughly 87% of peers on this dimension. EPS momentum scores are soft in the near term (13th percentile on 30-day, 23rd on 90-day), though forward EPS growth ranks better at the 65th percentile. The most recent earnings print, on August 25, saw the stock fall just 0.24% the following day before recovering 5% over the next five sessions — a pattern that rewarded holders who didn't panic at the headline reaction.
Institutionally, Aaron Levie — Box's CEO — trimmed 15,000 shares in a filing dated September 10. The sale is small relative to his 2.08% stake, but it is worth noting given the broader short buildup. BlackRock remains the dominant holder at 18.5%, and State Street and Acadian both added meaningfully in the most recent reporting period. Citadel built a position of over 1.38 million shares as of June 30, one of the larger incremental adds in the holder table.
The next earnings date is December 1. Between now and then, the key question is whether the short buildup — now at a one-month high — reflects genuine fundamental concern about Box's competitive position against Microsoft and others, or simply a hedge against a broader mid-cap software selloff: peers ADBE and WK both fell harder on the week at -7.6% and -6.7% respectively, while BOX dropped 5.5%, suggesting Box is not fully escaping the sector's gravity. How that gap behaves into December is what to watch.
See the live data behind this article on ORTEX.
Open BOX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
